APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/230,111	05/17/99	SATO	T	48962-A-PCT-

HM12/0919

JOHN P WHITE
COOPER & DUNHAM
1185 AVENUE OF THE AMERICAS
NEW YORK NY 10036

EXAMINER
BRUMBACK, B

ART UNIT	PAPER NUMBER
1642	12

DATE MAILED: 09/19/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/230,111	05/17/2000	Sato et al.	48962-A-PCT-US-JPW/EMW

EXAMINER	
Brenda Brumback	
ART UNIT	PAPER NUMBER
1642	12

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed 05/02/2000 is not fully responsive to the communication mailed 03/22/2000 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE (1) MONTH** or **THIRTY (30) DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda Brumback whose telephone number is (703) 306-3220. If the examiner can not be reached, inquiries can be directed to Supervisory Patent Examiner Anthony Caputa whose telephone number is (703) 308-3995. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Examiner Brenda Brumback, Art Unit 1642 and should be marked "OFFICIAL" for entry into prosecution history or "DRAFT" for consideration by the examiner without entry. The Art Unit 1642 FAX telephone number is (703)-305-3014. FAX machines will be available to receive transmissions 24 hours a day. In compliance with 1096 OG 30, the filing date accorded to each OFFICIAL fax transmission will be determined by the FAX machine's stamped date found on the last page of the transmission, unless that date is a Saturday, Sunday or Federal Holiday with the District of Columbia, in which case the OFFICIAL date of receipt will be the next business day.

Brenda Brumback
September 12, 2000

BRENDA BRUMBACK
PATENT EXAMINER

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

[X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

[ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

[ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

[X] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

[ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

[ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

[ ] 7. Other:

Applicant Must Provide:

[X] A substitute computer readable form (CRF) copy of the "Sequence Listing".

[X] A substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

[X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance...703-287-0200
To Purchase PatentIn Software.......................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Raw Sequence Listing Error Summary

ERROR DETECTED **SUGGESTED CORRECTION** **SERIAL NUMBER:** _0 9/Z 3o,///A_

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 _____ Wrapped Nucleics
The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

2 _____ Wrapped Aminos
The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

3 _____ Incorrect Line Length
The rules require that a line not exceed 72 characters in length. This includes spaces.

4 _____ Misaligned Amino Acid Numbering
The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
between the numbering. It is recommended to delete any tabs and use spacing between the numbers.

5 _____ Non-ASCII
This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.

6 _____ Variable Length
Sequence(s) _____ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.

7 _____ PatentIn ver. 2.0 "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) _____. Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence.

8 _____ Skipped Sequences (OLD RULES)
Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped ·

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).

9 _____ Skipped Sequences (NEW RULES)
Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

10 _____ Use of n's or Xaa's (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of **n** or **Xaa**, and which residue **n** or **Xaa** represents.

11 _____ Use of <213>Organism (NEW RULES)
Sequence(s) _____ are missing this mandatory field or its response.

12 _____ Use of <220>Feature (NEW RULES)
Sequence(s) _____ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of new Rules)

13 _____ PatentIn ver. 2.0 "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

NA

RE(Y643)

BATCH
1-28

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION *US/09/230,111*

DATE: 02/09/2000
TIME: 00:12:42

INPUT SET: S34674.raw

> This Raw Listing contains the General
> Information Section and up to the first 5 pages.

```
 1                              SEQUENCE LISTING
 2
 3   (1)     General Information:
 4
 5       (i) APPLICANT: Takaaki Sato and Junn Yanagisawa
 6
 7      (ii) TITLE OF INVENTION:  COMPOUNDS THAT INHIBIT THE
 8                                INTERACTION BETWEEN SIGNAL-TRANSDUCING
 9
10     (iii) NUMBER OF SEQUENCES: 33
11
12      (iv) CORRESPONDENCE ADDRESS:
13           (A) ADDRESSEE: Cooper & Dunham LLP
14           (B) STREET: 1185 Avenue of the Americas
15           (C) CITY: New York
16           (D) STATE: New York
17           (E) COUNTRY: U.S.A.
18           (F) ZIP: 10036
19
20       (v) COMPUTER READABLE FORM:
21           (A) MEDIUM TYPE: Floppy disk
22           (B) COMPUTER: IBM PC compatible
23           (C) OPERATING SYSTEM: PC-DOS/MS-DOS
24           (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
25
26      (vi) CURRENT APPLICATION DATA:
27           (A) APPLICATION NUMBER: Not Yet Known
28           (B) FILING DATE: 18-JUL-1997
29           (C) CLASSIFICATION:
30
31    (viii) ATTORNEY/AGENT INFORMATION:
32           (A) NAME: White, John P
33           (B) REGISTRATION NUMBER: 28,678
34           (C) REFERENCE/DOCKET NUMBER: 0575/48962-A-PCT-US
35
36      (ix) TELECOMMUNICATION INFORMATION:
37           (A) TELEPHONE: (212) 278-0400
38           (B) TELEFAX: (212) 391-0525
39
40
41   (2) INFORMATION FOR SEQ ID NO:1:
42
43       (i) SEQUENCE CHARACTERISTICS:
44           (A) LENGTH: 4 amino acids
45           (B) TYPE: amino acid
46           (C) STRANDEDNESS: single
```

PP. 2-3

Does Not Comply
Corrected Diskette Needed

--> OK

```
47                    (D)  TOPOLOGY: linear
48
49         (ii)  MOLECULE TYPE: peptide
50
51
52         (ix)  FEATURE:
53                    (A)  NAME/KEY: Peptide
54                    (B)  LOCATION: 1
55                    (D)  OTHER INFORMATION: /product= "OTHER"
56      /note= "Xaa= Gly/Ser/Ala/Glu"
57
58         (ix)  FEATURE:
59                    (A)  NAME/KEY: Protein
60                    (B)  LOCATION: 4
61                    (D)  OTHER INFORMATION: /product= "OTHER"
62      /note= "Xaa= Phe/Ile/Leu"
63
64
65         (xi)  SEQUENCE DESCRIPTION: SEQ ID NO:1:
66
67       Xaa Leu Gly Xaa
68       1
69
70   (2)  INFORMATION FOR SEQ ID NO:2:
71
72         (i)  SEQUENCE CHARACTERISTICS:
73                    (A)  LENGTH: 6 amino acids
74                    (B)  TYPE: amino acid
75                    (C)  STRANDEDNESS: single
76                    (D)  TOPOLOGY: linear
77
78         (ii)  MOLECULE TYPE: peptide
79
80
81         (ix)  FEATURE:
82                    (A)  NAME/KEY: Peptide
83                    (B)  LOCATION: 1
84                    (D)  OTHER INFORMATION: /product= "OTHER"
85      /note= "Xaa=Lys/Arg/Gln"
86
87         (ix)  FEATURE:
88                    (A)  NAME/KEY: Peptide
89                    (B)  LOCATION: 2
90                    (D)  OTHER INFORMATION: /product= "OTHER"
91      /note= "Xaa= Gly/Ser/Ala/Glu"
92
93         (ix)  FEATURE:
94                    (A)  NAME/KEY: Peptide
95                    (B)  LOCATION: 5
96                    (D)  OTHER INFORMATION: /product= "OTHER"
97      /note= "Xaa= Phe/Ile/Leu"
98
99
```

Gly is at location 5 — do you mean 6?
(next page)

```
100        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
101
102        Xaa Xaa Xaa Leu Gly Xaa
103        1                  5
104
105   (2) INFORMATION FOR SEQ ID NO:3:
106
107        (i) SEQUENCE CHARACTERISTICS:
108             (A) LENGTH: 4 amino acids
109             (B) TYPE: amino acid
110             (C) STRANDEDNESS: single
111             (D) TOPOLOGY: linear
112
113       (ii) MOLECULE TYPE: peptide
114
115      (iii) HYPOTHETICAL: NO
116
117       (iv) ANTI-SENSE: NO
118
119       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
120
121        Ser Leu Gly Ile
122        1
123
124
125   (2) INFORMATION FOR SEQ ID NO:4:
126
127        (i) SEQUENCE CHARACTERISTICS:
128             (A) LENGTH: 3 amino acids
129             (B) TYPE: amino acid
130             (C) STRANDEDNESS: single
131             (D) TOPOLOGY: linear
132
133       (ii) MOLECULE TYPE: peptide
134
135
136       (ix) FEATURE:
137             (A) NAME/KEY: Peptide
138             (B) LOCATION: 1
139             (D) OTHER INFORMATION: /product= "OTHER"
140   /note= "Xaa= Ser/Thr"
141
142       (ix) FEATURE:
143             (A) NAME/KEY: Peptide
144             (B) LOCATION: 3
145             (D) OTHER INFORMATION: /product= "OTHER"
146   /note= "Xaa= Val/Ile/Leu"
147
148
149       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
150
151        Xaa Xaa Xaa
152        1
```

```
153
154
155
156    (2) INFORMATION FOR SEQ ID NO:5:
157
158        (i) SEQUENCE CHARACTERISTICS:
159            (A) LENGTH: 15 amino acids
160            (B) TYPE: amino acid
161            (C) STRANDEDNESS: single
162            (D) TOPOLOGY: linear
163
164        (ii) MOLECULE TYPE: peptide
165
166        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
167
168        Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu Ile Gln Ser Leu Val
169        1               5                   10                  15
170
171
172    (2) INFORMATION FOR SEQ ID NO:6:
173
```

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION   *US/09/230,111*

INPUT SET: S34674.raw

Line	Error	Original Text
27	Wrong application Serial Number	(A) APPLICATION NUMBER: Not Yet Known